Author

J. Hooda

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Approach:deep learning· 1 Assay:DNA methylation· 1

Frequent Co-Authors

J. M. Atkinson· 4 shared S. Oesterreich· 4 shared A. V. Lee· 3 shared A. Elangovan· 2 shared L. Savariau· 2 shared M. E. Yates· 2 shared O. S. Shah· 2 shared P. F. McAuliffe· 2 shared

Activity by Year

2022-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

J. M. Atkinson

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Multi-omic characterization of ILC and ILC-like cell lines as part of ILC cell line encyclopedia (ICLE) defines new models to study potential biomarkers and explore therapeutic opportunities

O. S. Shah, F. Chen, A. Wedn, A. Kashiparekh, L. Savariau, B. Clifford, J. Hooda, M. Christgen, J. M. Atkinson, S. Oesterreich, A. V. Lee

The paper characterizes ILC and ILC-like cell lines through multi-omic analysis to identify molecular similarities with patient tumors and potential therapeutic targets.

bioRxiv · Sep 26, 2023 · PreprintCancer Biology

ESR1 fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypes

M. E. Yates, Z. Li, Y. Li, H. Guzolik, X. Wang, T. Liu, J. Hooda, J. M. Atkinson, A. V. Lee, S. Oesterreich

This study shows ER fusion proteins in breast cancer cell lines drive ligand-independent pro-oncogenic pathways, with subtype- and fusion-specific effects.

bioRxiv · Sep 18, 2023 · PreprintCancer Biology

WCRC-25: A novel luminal Invasive Lobular Carcinoma cell line model

A. Elangovan, E. A. Bossart, A. Basudan, N. Tasdemir, O. S. Shah, K. Ding, S. C. Purdy, C. Meier, T. Heim, C. Neumann, S. Attaran, L. Brown, J. Hooda, L. Miller, K. Kota, , S. Oesterreich

The paper introduces a new invasive lobular carcinoma cell line, WCRC-25, and demonstrates its molecular features and therapeutic response to PI3K/AKT inhibition.

bioRxiv · Sep 15, 2023 · PreprintCancer Biology

Loss of E-cadherin Induces IGF1R Activation Revealing a Targetable Pathway in Invasive Lobular Breast Carcinoma

A. Elangovan, J. Hooda, L. Savariau, S. Puthanmadhomnarayanan, M. E. Yates, J. Chen, D. D. Brown, P. F. McAuliffe, S. Oesterreich, J. M. Atkinson, A. V. Lee

This study shows that loss of E-cadherin in ILC leads to increased IGF1R activation and sensitivity to inhibitors, suggesting a therapeutic target and biomarker for ILC.

bioRxiv · Feb 22, 2022 · PreprintCancer Biology